Literature DB >> 9688300

Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic.

E Hamsíková1, V Ludvíková, M Smahel, M Sapp, V Vonka.   

Abstract

Sera from 450 individuals between the age of 1 and 80 years, representing the general population of the Czech Republic, were tested for the presence of antibodies to human-papillomavirus(HPV)-derived antigens. The following antigens were used: (i) HPV1 virions; (ii) HPV16, -18 and -33-virus-like particles (VLP); (iii) peptides derived from L2 open reading frames (ORFs) of HPV16 and HPV6/11; (iv) peptides derived from HPV16 E2, E4 and E7 ORFs of HPV16. The prevalence of antibodies reactive with the capsid-derived antigens was age-dependent, while no clear age dependence was observed in the distribution of antibodies to peptides derived from HPV16 early proteins. In individual sera, high correlations between the presence of antibodies reactive with the 2 L2 peptides, also between the antibodies reactive with different VLPs, were found. While the simultaneous presence of the 2 L2 antibodies was frequently detected in individual sera in all age groups, the simultaneous occurrence of VLP antibodies was detected mostly in subjects older than 20 years. There were no significant differences in HPV-antibody distribution between men and women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688300     DOI: 10.1002/(sici)1097-0215(19980831)77:5<689::aid-ijc5>3.0.co;2-r

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects.

Authors:  Jan Klozar; Ruth Tachezy; Eliška Rotnáglová; Eva Košlabová; Martina Saláková; Eva Hamšíková
Journal:  Wien Med Wochenschr       Date:  2010-06

2.  Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies.

Authors:  R Tachezy; I Mikysková; V Ludvíková; L Rob; T Kucera; V Slavík; A Beková; H Robová; M Pluta; E Hamsíková
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

Review 3.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

4.  Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue.

Authors:  Renwei Chen; Peter Sehr; Tim Waterboer; Ilmo Leivo; Michael Pawlita; Antti Vaheri; Leena-Maija Aaltonen
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

5.  Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic.

Authors:  Eva Hamsikova; Viera Ludvikova; Jana Stasikova; Ruth Tachezy
Journal:  Sex Transm Infect       Date:  2012-06-08       Impact factor: 3.519

6.  Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.

Authors:  Zuzana Humlová; Hana Klamová; Ivana Janatková; Karin Malíčková; Petra Králíková; Ivan Sterzl; Zdeněk Roth; Eva Hamšíková; Vladimír Vonka
Journal:  Clin Dev Immunol       Date:  2010-12-12

7.  Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.

Authors:  Anna Loenenbach; Michael Pawlita; Tim Waterboer; Thomas Harder; Christina Poethko-Müller; Michael Thamm; Raskit Lachmann; Yvonne Deleré; Ole Wichmann; Miriam Wiese-Posselt
Journal:  BMC Infect Dis       Date:  2022-01-10       Impact factor: 3.090

8.  Seroprevalence of 34 human papillomavirus types in the German general population.

Authors:  Kristina M Michael; Tim Waterboer; Peter Sehr; Annette Rother; Ulrich Reidel; Heiner Boeing; Ignacio G Bravo; Jörg Schlehofer; Barbara C Gärtner; Michael Pawlita
Journal:  PLoS Pathog       Date:  2008-06-20       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.